miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential

Sara E. Meyer; David E. Muench; Andrew M. Rogers; Tess J. Newkold; Emily Orr; Eric O’Brien; John P. Perentesis; John G. Doench; Ashish Lal; Patrick J. Morris; Craig J. Thomas; Judy Lieberman; Edwina McGlinn; Bruce J. Aronow; Nathan Salomonis; H. Leighton Grimes

doi:10.1084/jem.20171312

miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential

Sara E. Meyer, David E. Muench, Andrew M. Rogers, Tess J. Newkold, Emily Orr, Eric O’Brien, John P. Perentesis, John G. Doench, Ashish Lal, Patrick J. Morris, Craig J. Thomas, Judy Lieberman, Edwina McGlinn, Bruce J. Aronow, Nathan Salomonis, H. Leighton Grimes

Australian Regenerative Medicine Institute

Research output: Contribution to journal › Article › Research › peer-review

23 Citations (Scopus)

Abstract

We have shown that antagomiR inhibition of miRNA miR-21 and miR-196b activity is sufficient to ablate MLL-AF9 leukemia stem cells (LSC) in vivo. Here, we used an shRNA screening approach to mimic miRNA activity on experimentally verified miR-196b targets to identify functionally important and therapeutically relevant pathways downstream of oncogenic miRNA in MLL-r AML. We found Cdkn1b (p27 ^Kip1 ) is a direct miR-196b target whose repression enhanced an embryonic stem cell–like signature associated with decreased leukemia latency and increased numbers of leukemia stem cells in vivo. Conversely, elevation of p27 ^Kip1 significantly reduced MLL-r leukemia self-renewal, promoted monocytic differentiation of leukemic blasts, and induced cell death. Antagonism of miR-196b activity or pharmacologic inhibition of the Cks1-Skp2–containing SCF E3-ubiquitin ligase complex increased p27 ^Kip1 and inhibited human AML growth. This work illustrates that understanding oncogenic miRNA target pathways can identify actionable targets in leukemia.

Original language	English
Pages (from-to)	2115-2136
Number of pages	22
Journal	Journal of Experimental Medicine
Volume	215
Issue number	8
DOIs	https://doi.org/10.1084/jem.20171312
Publication status	Published - 1 Sept 2018

Access to Document

10.1084/jem.20171312

271197232-oaFinal published version, 2.84 MB

Cite this

Meyer, S. E., Muench, D. E., Rogers, A. M., Newkold, T. J., Orr, E., O’Brien, E., Perentesis, J. P., Doench, J. G., Lal, A., Morris, P. J., Thomas, C. J., Lieberman, J., McGlinn, E., Aronow, B. J., Salomonis, N., & Grimes, H. L. (2018). miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. Journal of Experimental Medicine, 215(8), 2115-2136. https://doi.org/10.1084/jem.20171312

@article{5e9469bf129c4603b9e0bdf0135fbae4,

title = "miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential",

abstract = " We have shown that antagomiR inhibition of miRNA miR-21 and miR-196b activity is sufficient to ablate MLL-AF9 leukemia stem cells (LSC) in vivo. Here, we used an shRNA screening approach to mimic miRNA activity on experimentally verified miR-196b targets to identify functionally important and therapeutically relevant pathways downstream of oncogenic miRNA in MLL-r AML. We found Cdkn1b (p27 Kip1 ) is a direct miR-196b target whose repression enhanced an embryonic stem cell–like signature associated with decreased leukemia latency and increased numbers of leukemia stem cells in vivo. Conversely, elevation of p27 Kip1 significantly reduced MLL-r leukemia self-renewal, promoted monocytic differentiation of leukemic blasts, and induced cell death. Antagonism of miR-196b activity or pharmacologic inhibition of the Cks1-Skp2–containing SCF E3-ubiquitin ligase complex increased p27 Kip1 and inhibited human AML growth. This work illustrates that understanding oncogenic miRNA target pathways can identify actionable targets in leukemia. ",

author = "Meyer, {Sara E.} and Muench, {David E.} and Rogers, {Andrew M.} and Newkold, {Tess J.} and Emily Orr and Eric O{\textquoteright}Brien and Perentesis, {John P.} and Doench, {John G.} and Ashish Lal and Morris, {Patrick J.} and Thomas, {Craig J.} and Judy Lieberman and Edwina McGlinn and Aronow, {Bruce J.} and Nathan Salomonis and Grimes, {H. Leighton}",

year = "2018",

month = sep,

day = "1",

doi = "10.1084/jem.20171312",

language = "English",

volume = "215",

pages = "2115--2136",

journal = "Journal of Experimental Medicine",

issn = "0022-1007",

publisher = "The Rockefeller University Press",

number = "8",

}

Meyer, SE, Muench, DE, Rogers, AM, Newkold, TJ, Orr, E, O’Brien, E, Perentesis, JP, Doench, JG, Lal, A, Morris, PJ, Thomas, CJ, Lieberman, J, McGlinn, E, Aronow, BJ, Salomonis, N & Grimes, HL 2018, 'miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential', Journal of Experimental Medicine, vol. 215, no. 8, pp. 2115-2136. https://doi.org/10.1084/jem.20171312

TY - JOUR

T1 - miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential

AU - Meyer, Sara E.

AU - Muench, David E.

AU - Rogers, Andrew M.

AU - Newkold, Tess J.

AU - Orr, Emily

AU - O’Brien, Eric

AU - Perentesis, John P.

AU - Doench, John G.

AU - Lal, Ashish

AU - Morris, Patrick J.

AU - Thomas, Craig J.

AU - Lieberman, Judy

AU - McGlinn, Edwina

AU - Aronow, Bruce J.

AU - Salomonis, Nathan

AU - Grimes, H. Leighton

PY - 2018/9/1

Y1 - 2018/9/1

N2 - We have shown that antagomiR inhibition of miRNA miR-21 and miR-196b activity is sufficient to ablate MLL-AF9 leukemia stem cells (LSC) in vivo. Here, we used an shRNA screening approach to mimic miRNA activity on experimentally verified miR-196b targets to identify functionally important and therapeutically relevant pathways downstream of oncogenic miRNA in MLL-r AML. We found Cdkn1b (p27 Kip1 ) is a direct miR-196b target whose repression enhanced an embryonic stem cell–like signature associated with decreased leukemia latency and increased numbers of leukemia stem cells in vivo. Conversely, elevation of p27 Kip1 significantly reduced MLL-r leukemia self-renewal, promoted monocytic differentiation of leukemic blasts, and induced cell death. Antagonism of miR-196b activity or pharmacologic inhibition of the Cks1-Skp2–containing SCF E3-ubiquitin ligase complex increased p27 Kip1 and inhibited human AML growth. This work illustrates that understanding oncogenic miRNA target pathways can identify actionable targets in leukemia.

AB - We have shown that antagomiR inhibition of miRNA miR-21 and miR-196b activity is sufficient to ablate MLL-AF9 leukemia stem cells (LSC) in vivo. Here, we used an shRNA screening approach to mimic miRNA activity on experimentally verified miR-196b targets to identify functionally important and therapeutically relevant pathways downstream of oncogenic miRNA in MLL-r AML. We found Cdkn1b (p27 Kip1 ) is a direct miR-196b target whose repression enhanced an embryonic stem cell–like signature associated with decreased leukemia latency and increased numbers of leukemia stem cells in vivo. Conversely, elevation of p27 Kip1 significantly reduced MLL-r leukemia self-renewal, promoted monocytic differentiation of leukemic blasts, and induced cell death. Antagonism of miR-196b activity or pharmacologic inhibition of the Cks1-Skp2–containing SCF E3-ubiquitin ligase complex increased p27 Kip1 and inhibited human AML growth. This work illustrates that understanding oncogenic miRNA target pathways can identify actionable targets in leukemia.

UR - http://www.scopus.com/inward/record.url?scp=85054724198&partnerID=8YFLogxK

U2 - 10.1084/jem.20171312

DO - 10.1084/jem.20171312

M3 - Article

C2 - 29997117

AN - SCOPUS:85054724198

SN - 0022-1007

VL - 215

SP - 2115

EP - 2136

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

IS - 8

ER -

miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential

Abstract

Access to Document

Other files and links

Cite this